Cure8 news brief
This study aims to show how mirikizumab and other biologics perform in everyday community practice — information that can help clinicians and patients understand real-world treatment durability, symptom control, and healthcare use outside clinical trials.
Real-world evidence may inform shared decision-making and care pathways.
Adults with Crohn’s disease or ulcerative colitis, patients on or considering biologic therapy (including mirikizumab), community gastroenterologists, and IBD researchers interested in real-world outcomes and comparative effectiveness.
Cardinal Health Real-World Data and Evidence and Eli Lilly launched INSIGHT-IBD, a prospective real-world evidence study tracking ~400 adults (half Crohn’s, half UC) across community gastroenterology practices to compare outcomes for patients receiving mirikizumab (Omvoh) versus other biologics.
Patients will be followed for 18 months each and the project spans three years, collecting EHR data, prospective data, and patient-reported outcomes including symptom relief, health status, work productivity, unplanned visits, and hospitalizations. Initial insights are expected within 6–8 months; the study has enrolled its first patient.
INSIGHT-IBD is an industry-collaborative real-world evidence study using EHRs, prospective collection, and surveys; real-world studies are observational and can show associations in routine care but do not establish causal effects like randomized trials.
The source is a Cardinal Health press release in partnership with Eli Lilly; early enrollment and planned interim insights are described, but full results are not yet available.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Knowing biomarkers that predict who will respond to IL23 p19 inhibitors could help people with IBD avoid trial-and-error therapy choices. Understanding whether increasing risankizumab dosing after loss of response...
ECCO 2026 presented multiple studies that could change IBD care across prevention, medical therapy (including pediatric data), complication‑directed strategies (perianal fistula), and technology‑assisted monitoring....
The study tests mirikizumab in routine clinical practice against standard biologic therapies to see if it lowers healthcare needs and improves symptoms and quality of life for people with Crohn’s disease or ulcerative...
